停药后病毒动力学在乙型肝炎e抗原阴性患者肝炎发作时机与严重程度中的作用
研究比较停用替诺福韦(TDF)与恩替卡韦(ETV)后乙型肝炎发作的病毒动力学差异。倾向评分匹配后,停用TDF组76%与停用ETV组15%发生早期发作;停用TDF组HBV DNA月升幅为2.12 log10 IU/mL、停用ETV组为0.73 log10 IU/mL(P < .01)。HBV DNA月升幅≥1 log10 IU/mL是发作更早、更严重的关键因素,≥2.5 log10 IU/mL为停用TDF后严重发作的独立因素。
要点
- 停用TDF后HBV DNA月升幅为2.12 log10 IU/mL,停用ETV后为0.73 log10 IU/mL(P < .01)。
- 停用TDF组76%与停用ETV组15%发生早期(<6个月)发作。
- HBV DNA月升幅≥1 log10 IU/mL是发作更早、更严重的关键因素。
核心结论
- HBV DNA月升幅≥1 log10 IU/mL是肝炎发作更早、更严重的关键因素。
- 停用TDF后HBV DNA月升幅≥1 log10 IU/mL者多于停用ETV,可能解释停用TDF后发作多较早且更严重。
- 对发作时HBV DNA月升幅≥1 log10 IU/mL者,尤其是早期停用TDF发作且≥2.5 log10 IU/mL者,更严密监测对及时再治疗以预防失代偿很重要。
研究设计与样本
- 招募停用ETV或停用TDF后发生肝炎发作的乙型肝炎e抗原阴性慢性乙型肝炎患者。
- 比较早期(<6个月)与晚期(6至24个月)发作患者的HBV动力学及发作严重程度。
- 在停用ETV与停用TDF发作间按年龄、性别、肝硬化、治疗结束时乙型肝炎表面抗原进行1:1倾向评分匹配。
主要发现
- 倾向评分匹配后,停用TDF的107例与停用ETV的107例中分别有76%和15%发生早期发作。
- 停用TDF发作的HBV DNA月升幅大于停用ETV发作(2.12 vs 0.73 log10 IU/mL;P < .01)。
- HBV DNA月升幅越大与发作时机越早及丙氨酸氨基转移酶峰值越高相关。
- HBV DNA月升幅≥2.5 log10 IU/mL为停用TDF后严重发作的独立因素。
- HBV DNA月升幅≥1 log10 IU/mL为停用ETV后严重发作的预测因素。
临床怎么用
- 对发作时HBV DNA月升幅≥1 log10 IU/mL者进行更严密监测,尤其早期停用TDF发作且≥2.5 log10 IU/mL者,以便及时再治疗预防失代偿。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatitis B flare occurs earlier and is more severe in patients stopping tenofovir (TDF) compared with entecavir (ETV). This study investigated relationship between hepatitis B virus (HBV) kinetics, onset timing, and the severity of flares. METHODS: Hepatitis B e antigen-negative chronic hepatitis B patients who developed off-ETV or off-TDF hepatitis flare were recruited. Their HBV kinetics and the severity of flares were compared between patients with early (<6 months) and late (between 6 and 24 months) flares. Propensity score matching was performed at 1:1 adjusting for age, sex, cirrhosis, and end-of-treatment (EOT) hepatitis B surface antigen between off-ETV and off-TDF flares. RESULTS: After propensity score matching, 76% and 15% of each 107 off-TDF and off-ETV patients, respectively, developed early flare. A much steeper HBV DNA upsurge (ΔHBV DNA/month) was observed in off-TDF than off-ETV flares (2.12 vs 0.73 log10 IU/mL; P < .01). Greater ΔHBV DNA/month correlated with earlier timing and higher peak alanine aminotransferase levels of flares. ΔHBV DNA/month ≥2.5 log10 IU/mL was an independent factor for severe off-TDF flare, and ≥1 log10 IU/mL was a predictor for severe off-ETV flares. CONCLUSIONS: Greater HBV DNA upsurge rate (ΔHBV DNA/month) ≥1 log10 IU/mL is a key factor for an earlier onset and more severe flare. More frequent ΔHBV DNA/month ≥1 log10 IU/mL in off-TDF than off-ETV flares may explain why off-TDF flare mostly occurred early and was more severe. More stringent monitoring in those with ΔHBV DNA/month ≥1 log10 IU/mL at flare, especially ≥2.5 log10 IU/mL in early off-TDF flares, is important for timely retreatment to prevent decompensation.
引用
- Liu YC, Jeng WJ, Peng CW, et al. The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients. Clin Gastroenterol Hepatol. 2022. PMID: 36038130. doi:10.1016/j.cgh.2022.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。